<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869905</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00156676</org_study_id>
    <nct_id>NCT03869905</nct_id>
  </id_info>
  <brief_title>Aquamin® as an Adjuvant Intervention for Ulcerative Colitis In Remission</brief_title>
  <official_title>Aquamin®, a Multi-mineral Natural Product From Red Marine Algae, as an Adjuvant Intervention for Ulcerative Colitis in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James Varani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Aquamin® works as a potential treatment to
      improve symptoms and if it will extend remission in patients with stable Ulcerative Colitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This pilot study includes individuals with ulcerative colitis in stable remission, and is a randomized, double-blind, placebo-controlled trial with two parallel treatment groups for the first 90 days. Subjects on placebo will be crossed over to Aquamin® after the halfway visit at day 90. Subjects on Aquamin® will continue their treatment till the end.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ulcerative colitis clinical features / presentation as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) score</measure>
    <time_frame>Up to day 180</time_frame>
    <description>This is a self-administered questionnaire. There are 32 quality of life questions related to bowel function. Each response corresponds to a letter 'a' through 'g'. Whereas 'a' indicates high frequency and 'g' indicates minimal frequency. The total IBDQ score ranges between 32 and 224, with higher scores indicating better quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in clinical assessment /gastroenterologist's endoscopic findings based on Ulcerative Colitis Disease Activity Index (UCDAI)/Mayo Scoring</measure>
    <time_frame>Up to day 180</time_frame>
    <description>UCDAI/Mayo Scoring consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0= normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cytokine levels of the colon tissue as measured by Interleukin 8 (IL-8) levels assessed by enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>Up to day 180</time_frame>
    <description>Interleukin 8 levels are measured in picograms per milliliter (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum C-reactive protein (CRP) levels as measured in a blood sample.</measure>
    <time_frame>Up to day 180</time_frame>
    <description>Serum C-reactive protein ([CRP levels)] will be reported in milligram per deciliter (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fecal calprotectin levels measured in a stool sample</measure>
    <time_frame>Up to day 180</time_frame>
    <description>Fecal calprotectin will be reported in microgram per gram (µg/g)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum liver function tests</measure>
    <time_frame>Up to day 180</time_frame>
    <description>Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and Alkaline Phosphatase (ALKP) assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Aquamin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be taken for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first then Aquamin®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: To be taken for the first 90 days. Aquamin®: To be taken for the last 90 days (after crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aquamin®</intervention_name>
    <description>4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)</description>
    <arm_group_label>Aquamin®</arm_group_label>
    <arm_group_label>Placebo first then Aquamin®</arm_group_label>
    <other_name>Nutritional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo first then Aquamin®</intervention_name>
    <description>4 capsules per day; 2 to be taken in the morning and 2 in the evening</description>
    <arm_group_label>Placebo first then Aquamin®</arm_group_label>
    <other_name>Maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ulcerative colitis with confirmed diagnosis by histology and endoscopy AND in stable
             remission for 3 months or more without therapy or with a maintenance therapy (except
             steroids and antibiotics for 3 months)

          -  A negative pregnancy test

        Exclusion Criteria:

          -  No history or diagnosis of any of the following conditions: Chron's disease, bleeding
             disorders, gastrointestinal or colonic malignancy, Kidney disease, including kidney
             &quot;stones&quot; or hypercalcemia, Coagulopathy/hereditary hemorrhagic disorders/ or receiving
             therapeutic doses of Coumadin or heparin.

          -  Ingested certain medications (Calcium, Vitamin D, fiber supplements and Non-steroidal
             anti-inflammatory drugs - NSAIDs) within 30 days of study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Varani</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Nadeem Aslam</last_name>
    <phone>734-936-1897</phone>
    <email>mnaslam@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muhammad N Aslam</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>James Varani</investigator_full_name>
    <investigator_title>Professor of Pathology</investigator_title>
  </responsible_party>
  <keyword>Remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

